Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2012 (2012), Article ID 912351, 5 pages
http://dx.doi.org/10.1155/2012/912351
Review Article

Update on Ppar 𝜸 and Nonalcoholic Fatty Liver Disease

Animal Science Laboratory, Orentreich Foundation for the Advancement of Science, 855 Route 301, Cold Spring, NY 10516, USA

Received 8 June 2012; Accepted 16 July 2012

Academic Editor: Manlio Vinciguerra

Copyright © 2012 Gene P. Ables. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common initial presentation of obesity and insulin resistance. Uninterrupted progression of hepatic lipid accumulation often leads to fatty liver disease and eventually cirrhosis. Insulin resistance is one of the characteristics of type 2 diabetes. Several types of treatment have been employed against type 2 diabetes some of which ameliorate NAFLD. The frequent line of treatment to improve insulin sensitivity is the use of thiazolidinediones (TZD) which activate the nuclear receptor, peroxisome proliferator activated receptor gamma (Pparγ). Although TZDs are proven to be very effective in promoting insulin sensitivity, its actions on Pparγ have been complicated, specifically on NAFLD. According to studies in different models, Pparγ manifests both beneficial and undesirable effects on NAFLD. This paper will focus on the current knowledge of Pparγ and its effect on NAFLD.